j*****7
发帖数: 4348 | 1 1) EXEL: ASCO上会有PE和记者招待会, poster大概下礼拜出来, 重点是XL-184. 照着公司管理层的说法, 今年肯定lock大于一个的partnership deal
2) ISIS: 六月二号公司召开年度大会, 届时将有三名专家到会, 会涉及mipomersen的
efficacy和SAFETY.
3) PLX: 年底前FDA应该会对taliglucerase alfa作出决定.
BTW, 发现了一个挺好的biotech company, Galapagos NV, 在比利时, 我想在IB下单,
可是不知道怎么会事, 单一下就被cancel了. | y***q
发帖数: 4147 | | h*****8
发帖数: 4754 | 3 谢过了。
着公司管理层的说法, 今年肯定lock大于一个的partnership deal
,
【在 j*****7 的大作中提到】
: 1) EXEL: ASCO上会有PE和记者招待会, poster大概下礼拜出来, 重点是XL-184. 照着公司管理层的说法, 今年肯定lock大于一个的partnership deal
: 2) ISIS: 六月二号公司召开年度大会, 届时将有三名专家到会, 会涉及mipomersen的
: efficacy和SAFETY.
: 3) PLX: 年底前FDA应该会对taliglucerase alfa作出决定.
: BTW, 发现了一个挺好的biotech company, Galapagos NV, 在比利时, 我想在IB下单,
: 可是不知道怎么会事, 单一下就被cancel了.
| y***q
发帖数: 4147 | | p*****6
发帖数: 55 | | p*****6
发帖数: 55 | | l**********e
发帖数: 3149 | | L**j
发帖数: 948 | | t*******o
发帖数: 1464 | 9 EXEL June5-7
Presentations Featuring XL184 (MET, VEGF, RET)
* Oral presentation: Data from a phase 2 study of XL184 in patients with
progressive glioblastoma will be presented on Saturday, June 5, 2010 from 5
* Oral presentation: Long-term results in a cohort of medullary thyroid
cancer patients in a phase 1 study of XL184 will be presented in a clinical
science symposium on Monday, June 7 at 10:45-11:00AM (Abstract #5502).
* Poster discussion: Data from a phase 1b/2 study of XL184 with and
without erlotinib in patients with non-small cell lung cancer will be
presented on Sunday, June 6, 2010 during the 2:00-6:00PM session with a
discussion from 5:00-5:15PM (Abstract #3017).
* Trials in Progress section: Data from an adaptive randomized
discontinuation trial of XL184 in patients with advanced solid tumors will
be presented on Monday, June 7, 2010 during the 8:00AM – 4:00PM session (
Abstract #TPS188).
Presentations Featuring XL147 (PI3K) and XL765 (PI3K, MTOR)
* Oral presentation: Data from a phase 1 dose-escalation study of XL147
administered orally to patients with advanced malignancies will be presented
in a clinical science symposium on Monday, June 7, 2010 from 8:30-8:45AM
local time (Abstract #3004).
* Poster discussion: Data from a phase 1 safety and pharmacokinetic
study of XL765 in combination with erlotinib in patients with advanced solid
tumors will be presented on Sunday, June 6, 2010 during the 2:00-6:00PM
session with a discussion from 5:00-5:15PM (Abstract #3015).
* Poster discussion: Data from a phase 1 dose-escalation study of the
safety, pharmacokinetics, and pharmacodynamics of XL765 administered orally
to patients with advanced malignancies will be presented on Sunday, June 6,
2010 during the 2:00-6:00PM session with a discussion from 5:45-6:00PM (
Abstract #3030).
* Poster presentation: Data from a phase 1 safety and pharmacokinetic
study of XL147 in combination with erlotinib in patients with advanced solid
tumors will be presented on Monday, June 7, 2010 during the 8:00AM – noon
session (Abstract #3070).
* Poster presentation: Data from a phase 1 safety and pharmacokinetic
study of XL147 in combination with paclitaxel and carboplatin in patients
with advanced solid tumors will be presented on Monday, June 7, 2010 during
the 8:00AM – noon session (Abstract #3078).
* Poster presentation: Data from a phase 1 safety and pharmacokinetic
study of XL765 in combination with temozolomide in patients with newly
diagnosed malignant glioma will be presented on Monday, June 7, 2010 during
the 8:00AM – noon session (Abstract #3085).
Additional Presentations Featuring Exelixis Compounds
* XL139 oral presentation: Data from a first-in-human, phase 1 study of
XL139 in subjects with advanced or metastatic solid tumors will be presented
in a clinical science symposium on Sunday, June 6, 2010 from 10:15-10:30AM
local time. Submitted for presentation by Bristol-Myers Squibb.
* XL228 poster presentation: Data from a phase 1 study of XL228, a
multitargeted protein kinase inhibitor, in patients with solid tumors or
multiple myeloma will be presented on Monday, June 7 from 8:00 AM – noon
session (Abstract #3105). | g*********1
发帖数: 725 | 10 谢银队。 ISIS看着可以开始潜伏了。
着公司管理层的说法, 今年肯定lock大于一个的partnership deal
,
【在 j*****7 的大作中提到】
: 1) EXEL: ASCO上会有PE和记者招待会, poster大概下礼拜出来, 重点是XL-184. 照着公司管理层的说法, 今年肯定lock大于一个的partnership deal
: 2) ISIS: 六月二号公司召开年度大会, 届时将有三名专家到会, 会涉及mipomersen的
: efficacy和SAFETY.
: 3) PLX: 年底前FDA应该会对taliglucerase alfa作出决定.
: BTW, 发现了一个挺好的biotech company, Galapagos NV, 在比利时, 我想在IB下单,
: 可是不知道怎么会事, 单一下就被cancel了.
| h*****8
发帖数: 4754 | 11 银队对大盘不看好，DIP买的都跑了。
【在 g*********1 的大作中提到】
: 谢银队。 ISIS看着可以开始潜伏了。
:
: 着公司管理层的说法, 今年肯定lock大于一个的partnership deal
: ,
| g*********1
发帖数: 725 | 12 生拉跟大盘关系不是很大吧，怎么全跑了？
【在 h*****8 的大作中提到】
: 银队对大盘不看好，DIP买的都跑了。
|
|
